Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 3/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24618063 | 0.93 | PARP15 (0.53) | PARP15PARP10PARP2TDP1APP | |
| SCHEMBL29024848 | 0.83 | PARP15 (0.64) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL20969745 | 0.81 | PARP15 (0.47) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL24783572 | 0.79 | APP (0.51) | APPCARM1PRMT6 | |
| SCHEMBL13948472 | 0.78 | ALDH1A1 (0.60) | TDP1APP | |
| SCHEMBL15169281 | 0.78 | ALDH1A1 (0.60) | TDP1APP | |
| SCHEMBL2665020 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL8930160 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL13135282 | 0.78 | HPGD (0.57) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL16838742 | 0.78 | TDP1 (0.73) | PARP15PARP10PARP2TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | PARP15 724/4885PARP10 753/4885PARP2 728/4885 |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | PARP15 724/4885PARP10 753/4885PARP2 728/4885 |
| US-10385047-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | PARP15 724/4885PARP10 753/4885PARP2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.